Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, CpG oligonucleotide treatment decreased tissue inhibitor of metalloproteinase-3 expression and increased levels of active MMP-13 in TLR9-expressing but not TLR9(-) breast cancer cells without affecting MMP-8.
|
16849519 |
2006 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We showed recently that TLR9 agonistic CpG-oligonucleotides (CpG-ODNs) induce matrix metalloproteinase-13 (MMP-13)-mediated invasion in TLR9-expressing (TLR9(+)) breast cancer cells.
|
17373717 |
2007 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, expression of TLR9 was studied in clinical breast cancer samples and normal breast epithelium with immunohistochemistry.
|
18922969 |
2008 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Single-nucleotide polymorphisms (SNPs) of Toll-like receptor (TLR) 2, TLR3, TLR4, and TLR9 genes, which are important for innate immunity, were analyzed for the association with breast cancer.
|
19810822 |
2009 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also confirmed the effect of CpG oligonucleotides on ERalpha-mediated transactivation in the breast cancer cell line MCF-7 forced to stably overexpress TLR9.
|
19724876 |
2009 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
When assessing the molecular activity of TLR9 in breast cancer, we found a strong positive correlation of nuclear factor-kappa B (NF-kappaB) activity with TLR9 mRNA expression (correlation coefficient r = 0.7, P < 0.001).
|
20156214 |
2010 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression levels of TLR3, TLR4 and TLR9 were analyzed on tumors from 74 patients with breast cancer.
|
21129170 |
2010 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We discovered that low tumor TLR9 expression is associated with significantly shortened disease-specific survival in patients with triple negative but not with ER+ breast cancers.
|
22847512 |
2012 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also studied TLR9 mRNA expression in archival breast cancer specimens (n = 12) with qRT-PCR, using primer sets that detect only the TLR9A isoform or the isoforms A and B (TLR9A/B).
|
21607583 |
2012 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We compared bisphosphonate effects in breast cancer cell lines with low or high TLR9 expression.
|
27888633 |
2016 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously showed that synthetic and self-derived DNA fragments induce TLR9-mediated breast cancer cell invasion in vitro.
|
26780557 |
2016 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, M13SV1-EGFP-Neo human breast epithelial cells, MDA-MB-435-Hyg human breast cancer cells and two hybrids M13MDA435-1 and -3 were investigated for TLR4 and TLR9 expression and signaling.
|
27187369 |
2016 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Three breast cancer cell-lines (MDA-MB-231, MCF7 and SKBR3) and five colorectal adenocarcinoma cell-lines (HT29, HT29/219, SW480, SW48 and SW1116) in addition to one primary foreskin isolated fibroblast cell were analyzed for cell surface and intracellular expression of TLR9 by flow cytometry method.
|
28106541 |
2017 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Since combination of Toll-like receptor (TLR) ligands could boost antitumor immunity, we evaluated the efficacy of dendritic cell (DC) vaccines upon dual activation of TLR9 and TLR7 in breast cancer models.
|
28432455 |
2017 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Germline TLR9 variants in European Americans (EAs) and AAs were investigated, to determine their contribution to AA breast cancer risk.
|
28886076 |
2017 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The major research questions: (1) How does cell free rDNA content change in breast cancer; (2) What type of response in the MCF7 breast cancer cells is caused by cf-rDNA; and (3) What type of DNA sensors (TLR9 or AIM2) is stimulated in MCF7 in response to the action of cf-rDNA?
|
31205871 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells.
|
31091800 |
2019 |